PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing

Gain expert perspectives on the current and future use of PARP inhibitors in metastatic breast cancer with this online program, which features an on-demand Webcast capturing a dynamic CCO symposium at SABCS 2018, downloadable slides from the symposium, and expert-authored commentaries. 
Mark E. Robson, MD
Lee Schwartzberg, MD, FACP

ClinicalThought

Have you started testing your patients with MBC for germline BRCA mutations? BRCA testing is important to guide treatment with PARP inhibitors.

Lee Schwartzberg, MD, FACP Released: September 21, 2018

Do you have questions about using PARP inhibitors as effectively as possible to treat your patients with breast cancer? Read expert answers to key questions from the audience at a recent symposium on PARP inhibition.

Mark E. Robson, MD Released: January 10, 2019

Are you curious about the next steps with PARP inhibitors for patients with breast cancer?

Lee Schwartzberg, MD, FACP Released: July 31, 2019
Jointly provided by National Comprehensive Cancer Network (NCCN) and Clinical Care Options, LLC
NCCN Logo

Karen Kanefield
Manager CE Accreditation & Program Operations
National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462

215-690-0239
215-690-0283 (Fax)
gianola@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

This activity is supported by educational grants from
AstraZeneca
Pfizer Inc.
Tesaro

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue